0JBU Stock Overview
A clinical-stage gene editing company, focuses on the development of curative genome editing treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Intellia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.16 |
| 52 Week High | US$28.09 |
| 52 Week Low | US$5.95 |
| Beta | 2.33 |
| 1 Month Change | 12.65% |
| 3 Month Change | -23.69% |
| 1 Year Change | -63.20% |
| 3 Year Change | -79.61% |
| 5 Year Change | -57.46% |
| Change since IPO | -62.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JBU | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 15.3% | -1.7% | 1.1% |
| 1Y | -63.2% | -16.2% | 2.2% |
Return vs Industry: 0JBU underperformed the UK Biotechs industry which returned -14.3% over the past year.
Return vs Market: 0JBU underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
| 0JBU volatility | |
|---|---|
| 0JBU Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 3.3% |
Stable Share Price: 0JBU's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0JBU's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 403 | John Leonard | www.intelliatx.com |
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
Intellia Therapeutics, Inc. Fundamentals Summary
| 0JBU fundamental statistics | |
|---|---|
| Market cap | US$952.97m |
| Earnings (TTM) | -US$525.91m |
| Revenue (TTM) | US$45.57m |
Is 0JBU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JBU income statement (TTM) | |
|---|---|
| Revenue | US$45.57m |
| Cost of Revenue | US$462.89m |
| Gross Profit | -US$417.32m |
| Other Expenses | US$108.59m |
| Earnings | -US$525.91m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.08 |
| Gross Margin | -915.80% |
| Net Profit Margin | -1,154.10% |
| Debt/Equity Ratio | 0% |
How did 0JBU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 22:55 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intellia Therapeutics, Inc. is covered by 42 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Brian Skorney | Baird |
| Huidong Wang | Barclays |